129 related articles for article (PubMed ID: 25559599)
1. Virological efficacy of a reduced dose of nevirapine in a small cohort of suppressed HIV-1-infected patients.
Lanzafame M; Lattuada E; Cucchetto G; Nicolè S; Concia E; Vento S
J Acquir Immune Defic Syndr; 2015 Apr; 68(4):e59-61. PubMed ID: 25559599
[No Abstract] [Full Text] [Related]
2. Raltegravir/nevirapine dual therapy at reduced doses as 'maintenance' treatment in virally suppressed HIV-infected patients.
Lanzafame M; Lattuada E; Rigo F; Nicole S; Cucchetto G; Vento S
AIDS; 2015 Aug; 29(13):1722-3. PubMed ID: 26372286
[No Abstract] [Full Text] [Related]
3. [Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients].
Zhou H; Zheng Y; He Y; Gong G; Chen Z; Liu M; Yin W; Liu C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Aug; 34(8):731-7. PubMed ID: 19734579
[TBL] [Abstract][Full Text] [Related]
4. Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and -RNA levels and CD4 cell gain.
Sarmati L; Parisi SG; Montano M; Andreis S; Scaggiante R; Galgani A; Viscione M; Maffongelli G; Ricciardi A; Andreoni C; Boros S; Palù G; Andreoni M
J Antimicrob Chemother; 2012 Dec; 67(12):2932-8. PubMed ID: 22915460
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of nevirapine + Kivexa (abacavir/lamivudine) as a simplification strategy for HIV patients with undetectable viral load.
Cabello Úbeda A; Sanz Moreno J; Williams F; Górgolas M
J Acquir Immune Defic Syndr; 2011 Nov; 58(3):e95-6. PubMed ID: 22005001
[No Abstract] [Full Text] [Related]
6. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.
Braithwaite RS; Kozal MJ; Chang CC; Roberts MS; Fultz SL; Goetz MB; Gibert C; Rodriguez-Barradas M; Mole L; Justice AC
AIDS; 2007 Jul; 21(12):1579-89. PubMed ID: 17630553
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?
Winston A; Pozniak A; Smith N; Fletcher C; Mandalia S; Parmar D; Gibbons S; Back D; Gazzard B; Nelson M
AIDS; 2004 Feb; 18(3):572-4. PubMed ID: 15090815
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
Swaminathan S; Padmapriyadarsini C; Venkatesan P; Narendran G; Ramesh Kumar S; Iliayas S; Menon PA; Selvaraju S; Pooranagangadevi NP; Bhavani PK; Ponnuraja C; Dilip M; Ramachandran R
Clin Infect Dis; 2011 Oct; 53(7):716-24. PubMed ID: 21890776
[TBL] [Abstract][Full Text] [Related]
10. Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program.
Idigbe EO; Adewole TA; Eisen G; Kanki P; Odunukwe NN; Onwujekwe DI; Audu RA; Araoyinbo ID; Onyewuche JI; Salu OB; Adedoyin JA; Musa AZ
J Acquir Immune Defic Syndr; 2005 Sep; 40(1):65-9. PubMed ID: 16123684
[TBL] [Abstract][Full Text] [Related]
11. Impact of the frequency of plasma HIV-1 RNA monitoring on the outcome of antiretroviral therapy.
Chaiwarith R; Praparattanapan J; Nuntachit N; Kotarathitithum W; Sirisanthana T; Supparatpinyo K
Curr HIV Res; 2011 Mar; 9(2):82-7. PubMed ID: 21361862
[TBL] [Abstract][Full Text] [Related]
12. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D;
HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients.
Zhou HY; Zheng YH; He Y; Chen Z; Liu M; Yin W; Liu C
Intervirology; 2010; 53(4):240-6. PubMed ID: 20357493
[TBL] [Abstract][Full Text] [Related]
14. Raltegravir-based regimens are effective in HIV-1 group O-infected patients.
Depatureaux A; Leoz M; Le Moal G; Pathé JP; Pavie J; Batisse D; Daneluzzi V; Genet P; Gerard L; Lascaux-Cametz AS; Lambolez T; Chennebault JM; Plantier JC
J Acquir Immune Defic Syndr; 2012 Sep; 61(1):e1-3. PubMed ID: 22918125
[No Abstract] [Full Text] [Related]
15. Baseline HIV RNA and the when to start question: time to stop asking this question?
Mussini C
AIDS; 2006 May; 20(8):1197-8. PubMed ID: 16691072
[No Abstract] [Full Text] [Related]
16. Effectiveness of etravirine-based therapy for treatment-experienced HIV-infected patients.
Huerta García G; Mata-Marín JA; Domínguez-Hermosillo JC; Chavez-García M; Banda-Lara MI; Nuñez-Rodríguez N; Cruz-Herrera JE; Sandoval-Ramírez JL; Villagómez-Ruiz A; Manjarrez-Tellez B; Gaytan-Martínez JE
J Infect Dev Ctries; 2016 Jun; 10(6):605-11. PubMed ID: 27367009
[TBL] [Abstract][Full Text] [Related]
17. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
Nachega JB; Hislop M; Dowdy DW; Gallant JE; Chaisson RE; Regensberg L; Maartens G
AIDS; 2008 Oct; 22(16):2117-25. PubMed ID: 18832875
[TBL] [Abstract][Full Text] [Related]
18. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
Lapadula G; Costarelli S; Quiros-Roldan E; Calabresi A; Izzo I; Carosi G; Torti C
Clin Infect Dis; 2008 Apr; 46(7):1127-9. PubMed ID: 18444839
[No Abstract] [Full Text] [Related]
19. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
[TBL] [Abstract][Full Text] [Related]
20. Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine.
Musiime V; Ssali F; Kayiwa J; Namala W; Kizito H; Kityo C; Mugyenyi P
AIDS Res Hum Retroviruses; 2009 Oct; 25(10):989-96. PubMed ID: 19778270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
